ReviewAmerican journal of cancer research2026
Unravelling SLC7 family members in thyroid cancer and translational barriers.
Review in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SLC7 family transporters are an important group of membrane proteins that facilitate the transport of different amino acids across the cell membrane. They have a crucial role in oncogenic signalling pathways, cellular metabolism, and redox balance. Previous literature had revealed the functions of SLC7 in breast, liver, prostate, and lung cancers, but the role of SLC7 family members in thyroid cancer remains unclear. Therefore, this review investigated the emerging roles of SLC7, the molecular mechanisms underlying thyroid cancer progression, and strategies to improve its therapeutic delivery. In thyroid cancer, mutations in SLC7 subunits could further dysregulate amino acid metabolism and activate the PI3K/AKT, mTORC1, and MAPK/ERK signalling pathways. The activation of oncogenic signals, such as MYC, ATF4, and HIF-1α, could further enhance the SLC7 expression by promoting tumour progression, angiogenesis, and cell proliferation, impairing T-cell activation, and inhibiting the activities of natural killer cells (NK) and cytotoxic T-lymphocytes (CTLs). They also served as potential therapeutic agents, and modulating them with novel immune checkpoint inhibitors, engineered CAR-T cells, and CRISPR-edited cells represents a promising strategy for thyroid cancer treatment. The present review could explore innovative insights into the molecular mechanisms of SLC7 in thyroid cancer development, identify the novel therapeutic targets, and improve their delivery for thyroid cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.